The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.

MLA

Beebe, Kirk D., et al. “The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.” Journal of Immunology (Baltimore, Md. : 1950), vol. 213, no. 1, July 2024, pp. 29–39. EBSCOhost, https://doi.org/10.4049/jimmunol.2300736.

APA

Beebe, K. D., Eisner, J. R., Guo, J., Shibata, Y., Davison, J. M., Uronis, J., Farhangfar, C., Farhangfar, F., Mooney, J., Milburn, M. V., White, R. L., Amin, A., Milla, M. E., & Foureau, D. M. (2024). The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies. Journal of Immunology (Baltimore, Md. : 1950), 213(1), 29–39. https://doi.org/10.4049/jimmunol.2300736

Chicago

Beebe, Kirk D, Joel R Eisner, John Guo, Yoichiro Shibata, James M Davison, Josh Uronis, Carol Farhangfar, et al. 2024. “The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.” Journal of Immunology (Baltimore, Md. : 1950) 213 (1): 29–39. doi:10.4049/jimmunol.2300736.